AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04382079 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: honey
Description: Since the patient received radiation therapy, Taiwan Longan Honey has been used for a total of eight weeks.~Understand the changes of oral mucositis and various symptoms during this period
Study NCT04382079 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: propolis
Description: Since the patient received radiation therapy, Taiwan green propolis has been used for a total of eight weeks.~Understand the changes of oral mucositis and various symptoms during this period
Study NCT02473263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: Ceftriaxone 2g IV will be infused in the first 60 minutes, for non nosocomial severe septic syndrome
Study NCT02473263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin tazobactam
Description: Piperacillin/tazobactam 4g IV will be infused in the first 60 minutes, for nosocomial severe septic syndrome
Study NCT02473263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine will be infused after failure of hemodynamic optimization using vascular fluid loading
Study NCT02473263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone 100mg IV will be infused after failure of hemodynamic optimization using norepinephrine with at least 1.5mg/h
Study NCT01433003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma Exchange
Description: Plasma exchange is a blood purification technique that removes plasma from the blood and replaces it with donor plasma.
Study NCT01433003 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasma Exchange
Description: Plasma exchange is a blood purification technique that removes plasma from the blood and replaces it with donor plasma.
Study NCT00067873 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Study NCT00067873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Study NCT00067873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Study NCT00067873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Study NCT00300495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Description: Perioperative orally administered
Study NCT00300495 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control arm, standard care
Description: Control
Study NCT03250520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum acetylacetonate (1% wt) supported by sol-gel technology functionalized titania
Description: Sol-gel process Pt(acac)2- F-TiO2 nanostructured material with antitumoral activity used as an alternative in the treatment of cancer tumors. The biocatalysts were prepared by the sol-gel route using the complex Pt(acac)2.
Study NCT00720707 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF+ADM+EMD
Description: using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) with enamel matrix derivatives (EMD).
Study NCT00720707 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF+ADM
Description: using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) without enamel matrix derivatives (EMD) for root coverage procedures.
Study NCT04886830 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic appendectomy using a single endoloop for appendiceal stump closure
Description: laparoscopic appendectomy using a single endoloop for appendiceal stump closure before resecting the appendix
Study NCT04886830 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic appendectomy using two endoloops for appendiceal stump closure
Description: laparoscopic appendectomy using a two endoloops for appendiceal stump closure before resecting the appendix
Study NCT03996421 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutritional iron (14 mg) supplement in form of ferrous fumarate
Description: nutritional iron (14 mg) supplement in form of ferrous fumarate
Study NCT03996421 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous fumarate + 15 g GOS
Description: nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g GOS)
Study NCT01176942 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic bacterium Bifidobacterium lactis
Description: Probiotic placebo controlled intervention
Study NCT04364971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: singleradius and multiradius total knee arthroplasty
Description: singleradius and multiradius total knee arthroplasty
Study NCT01300065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental- Soflens
Description: A new pair of lenses will be worn each day while the subject is in the study
Study NCT01300065 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed - Soflens
Description: A new pair of lenses will be worn each day while the subject is in the study.
Study NCT03896932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: minipooled- Intravenous immunoglobulin(MP-IVIG)
Description: The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our CBTS in AUH. The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters.
Study NCT01163877 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fe-57 orally, Fe-58 intravenously
Description: Subjects will receive a test drink containing 3 mg Fe-57 in the form of labelled FeSO4 followed by 1 ml of an aqueous solution containing 50 μg Fe-58 as iron citrate.
Study NCT01783873 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™)
Description: At Visit 1: Patients are selected and they will receive a metacholine challenge test during and outside of work. After randomization, patients undergo a standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™) to either an wheat flour allergen extract or didecyldimethylammonium chloride or placebo. Each bronchial challenge test is followed by blood sampling at different time points and induced sputum. The immediate bronchial response and late bronchial response will be recorded.
Study NCT01783873 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™)
Description: At Visit 1: Patients are selected and they will receive a metacholine challenge test during and outside of work. After randomization, patients undergo a standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™) to either an wheat flour allergen extract or didecyldimethylammonium chloride or placebo. Each bronchial challenge test is followed by blood sampling at different time points and induced sputum. The immediate bronchial response and late bronchial response will be recorded.
Study NCT02452658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Changed menu
Description: After making the hypothetical choice, participants will be exposed to a menu with changed calorie and price labels, as well as several other changes.
Study NCT01176942 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic bacterium Bifidobacterium lactis
Description: Probiotic placebo controlled intervention
Study NCT04886830 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic appendectomy using a clip for appendiceal stump closure
Description: laparoscopic appendectomy using an endoclip for appendiceal stump closure before resecting the appendix
Study NCT06694038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Needle Knife Fistulotomy
Description: Biliary access using needle knife fistulotomy technique
Study NCT06694038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard biliary cannulation
Description: standard biliary cannulation
Study NCT01511237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine, zidovudine, lamivudine
Description: * Mothers: One NVP 200 mg tablet at onset of labor with continuation of HAART for four weeks postpartum~* Newborn: AZT+3TC+ NVP for 2 weeks, followed by AZT+3TC for 2 weeks:~  * NVP syrup 2 mg/kg every 24 hours for seven days, followed by NVP syrup 4 mg/kg every 24 hours for seven days. Newborns less than 2500 g will be administered 2mg/kg NVP syrup at each intake~ * AZT syrup 4 mg/ kg will be given every 12 hours for four weeks (preterm infants less than 30 weeks will be administered 2 mg/kg every 12 hours; preterm 30-35 weeks will receive 2 mg/kg every 12 hours for the first 2 weeks, increased to 3 mg/kg for the next 2 weeks).~ * 3TC syrup 2 mg/kg every 12 hours for four weeks.
Study NCT01791296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: At 21:30h, all current IV sedatives (whether continuous or intermittent) will be decreased by 50% and study drug started at 0.2 mcg/kg/hour at 21h30 to allow sleep between 22h00 and 6h00. Study infusion will be halved at 6:00am and d/c at 6:15am. The infusion rate will be increased by 0.1mcg/kg/hour every 15 minutes when the Riker-SAS is ≥ 4 up to a maximum rate of 0.7 mcg/kg/hr until the targeted sedation goal of a Riker-SAS of 3 is reached. For agitation (ie., Riker-SAS ≥ 5), 'as needed' IV midazolam (1-5 mg IV q1h prn agitation) may be administered during the upwards titration of the study medication. Administration of any dose of as needed IV midazolam will result in the increase of the study medication by 0.1 mcg/kg/hr when ≥ 15 minutes have elapsed since the last upwards titration.
Study NCT01791296 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At 21:30h, all current IV sedatives (whether continuous or intermittent) will be decreased by 50% and study drug started at 0.2 mcg/kg/hour at 21h30 to allow sleep between 22h00 and 6h00. Study infusion will be halved at 6:00am and d/c at 6:15am. The infusion rate will be increased by 0.1mcg/kg/hour every 15 minutes when the Riker-SAS is ≥ 4 up to a maximum rate of 0.7 mcg/kg/hr until the targeted sedation goal of a Riker-SAS of 3 is reached. For agitation (ie., Riker-SAS ≥ 5), 'as needed' IV midazolam (1-5 mg IV q1h prn agitation) may be administered during the upwards titration of the study medication. Administration of any dose of as needed IV midazolam will result in the increase of the study medication by 0.1 mcg/kg/hr when ≥ 15 minutes have elapsed since the last upwards titration.
Study NCT01801969 — intervention group
Intervention type: OTHER
Intervention: Rehabilitation service
Description: * Centralized/ decentralized hospital based rehabilitation defined as hospital based rehabilitation in a single or in multiple locations, respectively.~* Size of the municipality responsible for providing rehabilitation services after discharge from hospital
Study NCT02609906 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PhilosTM with augmentation (Depuy-Synthes)
Description: All fractures will initially be immobilised by a Gilchrist-bandage. This is the same procedure as for patients who do not attend this or any other trial and will be performed by the doctor on-duty in the emergency room. Patients will be admitted to the trauma ward after that. On the same day or at the latest on day after this patients will be informed about the current investigation, screened, included and randomized by one of the study doctors to our trial after written consent will be obtained as described above.~Operative treatment is exclusively performed by the below mentioned study doctors. This group will be treated by the angle stable plate fixation system PhilosTM with augmentation (Depuy-Synthes).
Study NCT04159727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stool and blood analysis
Description: High throughput sequencing and quantitative PCR
Study NCT04159727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stool and blood analysis
Description: High throughput sequencing and quantitative PCR
Study NCT04272853 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Compilation of the interview concerning: demographic data, sports practice, habits on sleep, sexual habits, perception of the relationship between sexual habits and sleep, perception of the relationship between sexual habits and sports practice.
Study NCT02609906 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MultiLoc®-Nail (Depuy-Synthes)
Description: All fractures will initially be immobilised by a Gilchrist-bandage. This is the same procedure as for patients who do not attend this or any other trial and will be performed by the doctor on-duty in the emergency room. Patients will be admitted to the trauma ward after that. On the same day or at the latest on day after this patients will be informed about the current investigation, screened, included and randomized by one of the study doctors to our trial after written consent will be obtained as described above.~Operative treatment is exclusively performed by the below mentioned study doctors. This group will be treated by the multiplanar proximal humeral nail MultiLoc® (Depuy-Synthes).
Study NCT02563210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: airway resistance measurement
Description: assessment of airway resistance
Study NCT02571855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 (hydrochloride salt)
Description: Hard-gelatin capsules (strength: 5 mg and 25 mg)
Study NCT02571855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 (free base)
Description: Soft capsules (strength: 25 mg)
Study NCT02571855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matching the ACT-541468 formulations
Study NCT01245049 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix PolioTM
Description: Single dose, intramuscular administration.
Study NCT00791128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GI Liner
Description: Medical device placed endoscopically in the duodenum, nutritional counseling
Study NCT02599389 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-coated balloons
Study NCT02599389 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excimer Laser
Study NCT00722059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Tomosynthesis
Description: 3D breast imaging
Study NCT01245049 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RepevaxTM
Description: Single dose, intramuscular administration.
Study NCT01245049 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PriorixTM
Description: Single dose, intramuscular or subcutaneous administration.
Study NCT01245049 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PriorixTM
Description: Single dose, intramuscular or subcutaneous administration.
Study NCT01319461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyalgan
Description: Patients will receive intraarticular injection of 20mg /2ml /syringe Hyalgan® once a week for 5 consecutive weeks.
Study NCT01319461 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sterile normal saline
Description: Patients will receive intraarticular injection of sterile normal saline once a week for 5 consecutive weeks.
Study NCT04632030 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco power wall size and tobacco products displayed
Description: The intervention varies the size of the tobacco power wall and number of tobacco products displayed on it.
Study NCT04632030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco power wall size and tobacco products displayed
Description: The intervention varies the size of the tobacco power wall and number of tobacco products displayed on it.
Study NCT03556878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitted Transdiagnostic Sleep and Circadian intervention
Description: Fitted TranS-C is an adapted version is designed to improve the fit with community needs and resources.
Study NCT03383081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose mesenchymal stem cells
Description: Human umbilical cord mesenchymal stem cells (SCLnow 19#): group A, 1 \* 10\^7 cells (5ml);
Study NCT03383081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose mesenchymal stem cells
Description: Human umbilical cord mesenchymal stem cells (SCLnow 19#): group B, 2 \* 10\^7 cells (5ml)
Study NCT03383081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraarticular injection
Description: Intraarticular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#) with different dose group
Study NCT00527878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: Double blinded, randomized placebo controlled crossover study. Patients received 12 months of placebo and 12 months of treatment medication (ranitidine).
Study NCT00527878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT04495478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ramucirumab - IV
Description: Administered IV.
Study NCT04495478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - IV
Description: Administered IV.
Study NCT04495478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ramucirumab - SC
Description: Administered SC.
Study NCT04495478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab - SC
Description: Administered SC.
Study NCT04495478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - SC
Description: Administered SC.
Study NCT00969085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin (Turmeric)
Description: Chew then swallow 2 sticks per day for up to 6 months.~2 sticks = 1 packet of curcumin = 8 grams
Study NCT00969085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Quality of life (QOL) questionnaires completed on Day 1, Weeks 2, 4, 8, 12, 16, 20, and at end of treatment visit.
Study NCT00969085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photos
Description: Photos of up to 6 selected skin lesion(s) and half-body photos taken on Day 1, Weeks 2, 4, 12, and at end of treatment visit.
Study NCT03971045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will be treated with pembrolizumab administered as an intravenous infusion at 200 mg in 21-day treatment cycles and oral cyclophosphamide (CTX) 50 mg per day in metronomic administration as a 21 days cycle
Study NCT04514549 — intervention group
Intervention type: DEVICE
Intervention: Emerald
Description: The Emerald is a wireless sensor that can track the motion, breathing, and sleep of subjects without touching or requiring any interaction with the subjects, allowing them to go about their normal lives. The physical device is roughly a 30 x 35 x 5 cm box that contains directional antennas and a motherboard to process these signals. In typical operation, the device is mounted onto a wall within a clinic or home setting using peel-away (reversible) mount strips.
Study NCT03921541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegzilarginase
Description: Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
Study NCT03921541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
Study NCT03965299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VERUM TTNS
Description: * Daily 30-minute TTNS intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments~* During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase
Study NCT03965299 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM TTNS
Description: * Daily 30-minute SHAM intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments~* During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase
Study NCT03388788 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET Imaging
Description: Positron Emission Tomography (PET) imaging for research.
Study NCT03388788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circadian Study Protocol
Description: 5-day circadian study schedule
Study NCT03388788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-Meta-Hydroxyephedrine (mHED)
Description: 11C-meta-hydroxyephedrine will be used during PET imaging to measure cardiac presynaptic norepinephrine transporter function.
Study NCT03388788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-CGP12177
Description: Cardiac beta adrenergic receptor density will be measured via PET imaging with infusion of 11C-CGP12177.
Study NCT03388788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O15-water
Description: Blood flow will be measured via PET imaging with infusion of O15-water.